Literature DB >> 21373976

The R5 to X4 coreceptor switch: a dead-end path, or a strategic maneuver? Lessons from a game theoretic analysis.

Sharon Bewick1, Jing Wu, Scott C Lenaghan, Ruoting Yang, Mingjun Zhang, William Hamel.   

Abstract

In this paper, we show how a game theoretic analysis can provide a model to explain the interdependence of host produced APOBEC3G levels and virus encoded Vif levels. We then use the relationship between these two opposing proteins in order to predict the success of two different HIV-1 viral variants, R5 and X4. From our analysis, we show that when APOBEC3G strongly favors mutation from an R5 strain to an X4 strain, it can be optimal for HIV-1 to suppress transmission of the X4 variant, despite the loss of X4 fitness potential. This is particularly true when the X4 strain significantly interferes with the host adaptive immune response, when Vif production is limited, or when host APOBEC3G targets the X4 strain more severely than the R5 strain. Using the proposed game theoretic analysis, we show that transmitting only R5 viruses has two advantages so far as HIV-1 is concerned. First, it allows for an increased R5 viral load due to immune interference caused by the X4 strain, and second, it forces the host to down-regulate APOBEC3G production, which is automatically favorable to the virus. APOBEC3G down-regulation, which is predicted in our model for a wide range of parameter values, may offer an explanation for the observed low level of APOBEC3G transcription and translation in hosts infected with HIV-1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21373976     DOI: 10.1007/s11538-010-9625-1

Source DB:  PubMed          Journal:  Bull Math Biol        ISSN: 0092-8240            Impact factor:   1.758


  1 in total

1.  Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPT.

Authors:  Rafael Van den Bergh; Sébastien Morin; Hans Jürgen Sass; Stephan Grzesiek; Marc Vekemans; Eric Florence; Huyen Thanh Thi Tran; Rosina Gabriel Imiru; Leo Heyndrickx; Guido Vanham; Patrick De Baetselier; Geert Raes
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.